Home › Encyclopedia › Carbetocin: Research Status and Clinical Trial Data
Research / Unapproved

Carbetocin: Research Status and Clinical Trial Data

Drafted by an automated content engine from FDA, PubChem, ClinicalTrials.gov, NIH DSLD, and Open Beauty Facts data.

Molecular formulaC45H69N11O12S
Molecular weight988.2 g/mol
Registered trials107
PubChem CID16681432

Key takeaways

  • Carbetocin is an investigational compound with no FDA-approved label in this dataset.
  • It has been registered in 107 clinical trials.
  • Sampled trials span postpartum hemorrhage research and Prader-Willi syndrome studies.
  • One sampled Phase 3 trial in Prader-Willi syndrome has reached completed status.

What carbetocin is

Carbetocin is a synthetic peptide compound identified by PubChem CID 16681432, with a molecular formula of C45H69N11O12S. No approved drug label is associated with this compound in the data reviewed, and it is classified here as an unapproved research compound. This means the summaries below describe research activity only, not an established medical use.

Trial footprint

Carbetocin appears across 107 registered clinical trials. Sampled studies include a multicentric randomized trial comparing carbetocin with oxytocin and misoprostol for postpartum hemorrhage treatment, currently listed with unknown status. A Phase 3 trial of intranasal carbetocin (LV-101) in patients with Prader-Willi syndrome is recorded as completed. A separate ex-vivo study is recruiting to compare dose-response profiles of uterotonics following initial carbetocin administration in desensitized human myometrium tissue.

FAQ

Is carbetocin FDA-approved?
Based on the data reviewed, carbetocin does not have an FDA-approved label in this dataset. It is classified as an investigational or unapproved research compound, meaning its use is limited to clinical research settings rather than approved medical treatment.
What conditions is carbetocin being studied for?
Sampled trials show carbetocin studied in postpartum hemorrhage management alongside oxytocin and misoprostol, and separately in Prader-Willi syndrome. An additional ex-vivo study is examining uterine tissue response following carbetocin exposure.
How many clinical trials involve carbetocin?
The compound has been registered in 107 clinical trials to date. These span different research areas and trial phases, reflecting ongoing investigational interest.
Has any carbetocin trial been completed?
Yes, a Phase 3 trial evaluating intranasal carbetocin (LV-101) in patients with Prader-Willi syndrome is listed as completed. Other sampled trials remain in recruiting or unknown status.
What is the chemical identity of carbetocin?
Carbetocin is a synthetic peptide with the molecular formula C45H69N11O12S, cataloged under PubChem CID 16681432. This chemical identity applies to the research compound described in the available data.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem ClinicalTrials.gov

Updated 2026-08-03